Rockwell Medical is trying to prove that a hemodialysis-concentrates franchise still has a commercial engine after its largest customer walked most of the volume off the truck. DaVita, which once accounted for nearly half of product sales, has receded to a mid-single-digit share of the first half, and the second-quarter print is the first clean look at whether Western independents, skilled-nursing operators, and multi-year purchase agreements can fill that hole. Management describes a stronger customer mix, a leaner plant footprint, and a cash-generative quarter relative to a year ago. The equity debate is narrower than the old iron-therapy story: it is whether a smaller, more diversified concentrates book can expand gross margin and print the guided adjusted earnings before interest, taxes, depreciation, and amortization before the remaining DaVita agreement expires at year-end.
The quarter did some of the work the rebuild needs and left some of it unfinished. Net sales of $17.8 million rose versus the year-ago quarter and versus the first quarter. Gross margin reached 18 percent on lower manufacturing headcount after the South Carolina plant closed. Operating cash flow of $2.1 million turned the quarter cash-generative. Cash and investments sat at $24.8 million at mid-year, near the prior year-end level. The first-half top line was essentially unchanged because the DaVita reduction, including a prior-year price adjustment that did not repeat, offset almost all of the new-customer and price gains. Adjusted earnings before interest, taxes, depreciation, and amortization stayed slightly negative, so the profitability conversion the guidance assumes is still a second-half event.
What the next two quarters have to show is not another sequential sales tick. They have to show that eighteen-percent gross margin holds as volume mixes toward smaller accounts, that administrative cost does not eat the plant savings, and that the Heritage Dialysis and aQua Dialysis contracts plus the Innovative Renal Care book convert into a run rate that supports the seventy-to-seventy-five million sales guide. The counterargument is simple. This is still a loss-making specialty manufacturer with a year-end customer cliff, a term loan from Innovatus, and an unused at-the-market facility sitting over a post-split share count. The second half either closes the profitability gap or the DaVita residual keeps shrinking faster than the replacement book can grow.